Introduction
============

The incidence of invasive fungal infections has increased during the past three decades, arising more and more concern. For example, statistics show that such incidence ranges from 30 to 40% throughout critical ill patients ([@B8]). Prognosis of invasive fungal infections is serious. Specifically, the mortality rate of systemic *C. albicans* infection is up to 40% ([@B59]). Risk factors, such as gastrointestinal surgery, widespread use of broad-spectrum antibiotics and popularization of central venous catheters (CVCs) mainly contribute to the invasive *C. albicans* infection. At the same time, non-*Candida* fungal infections should not be neglected, as cryptococcosis is the third prevalent disease in HIV-positive patients, and the mortality of invasive aspergillosis at 30 days in adult ICU patients is estimated to be 33.1% ([@B87]; [@B7]).

Represented by azole resistance, the continuous emergence of drug-resistant fungal strains has become a serious challenge for public health ([@B186]). CYP51 (ERG11) proteins is the target of azoles, which mediates membrane permeability and fluidity by demethylating the 14-α position of lanosterol to form ergosterol ([@B39]). In attribution to the constant emergence of azole-resistant isolates, a critical understanding of the resistance mechanisms of CYP51 is required for the discovery of novel CYP51 inhibitors.

Function and Structural Features of Fungal CYP51S
=================================================

Sterol synthesis is a very ancient pathway. After the appearance of molecular oxygen in the atmosphere, squalene-2,3-epoxide is formed and then cyclized to steroid precursors, such as lanosterol. Under the oxidative removal of methyl groups by CYP51, these precursors were transformed into ergosterol, which is critical in membrane permeability and fluidity in the fungal kingdom ([@B132]; [@B39]).

Cytochrome P450s (P450s, CYP) are an abundant hemease superfamily. As the first group of enzymes ranked as "superfamily," cytochrome P450s play an important role in the primary as well as secondary metabolic pathways ([@B84]). Until August 2013, this superfamily contained 10 classes, 267 families and over 21,000 members. These members are important for catalyzing the oxidative process of various organic substrates, and play a critical role during heterogeneous metabolism and steroid conversion in biological kingdoms ([@B64]; [@B114]).

CYP51 proteins belong to the CYP superfamily and is the most conserved protein in it. Unlike other CYP enzymes, CYP51 has a strong specificity. It only catalyzes the demethylation of a very narrow range of substrates, including lanoserol, obtusifoliol, 24,25-dihydrolanosterol, 24-methylenedihydrolanosterol and 4 β-desmethyllanosterol ([@B90]). The CYP51-involved catalytic reaction consists of three steps, each of which requires one molecule of oxygen and two molecules of NADPH-sourced reduction equivalent. The first two steps are typical cytochrome P450 monooxygenation processes, during which the 14α methyl is converted to methyl alcohol and further converted to methyl aldehyde. And in the last step, the aldehyde group is transformed into formic acid and detached, accompanied with the synthesis of the Δ-14, 15 double bond ([@B169]).

The 14α-demethylase is the only invariant P450 present in all sterol biosynthetic pathways, suggesting that all sterol 14α-demethylases share a common prokaryotic ancestor ([@B90]). CYP51s are widely distributed in the fungal kingdom. However, in different species of fungi, there are still differences in the types and subtypes, as shown in the phylogenetic tree ([@B128]) ([Figure 1](#F1){ref-type="fig"}). Only one CYP51 gene exists in the pathogenic fungi *C. albicans*, which belongs to the *Ascomycota Saccharomycotina* ([@B69]). In contrast, 2 or 3 *CYP51* genes are commonly contained in the *Ascomycota Pezizomycotina* genomes, including *CYP51A* and *CYP51B*. *CYP51C* is exclusive in *Fusarium* spp. ([@B9]). Some *Aspergillus* Spp. such as *A. fumigatus* carries only one CYP51A and one CYP51B protein, while other *Aspergillus* species such as *A. flavus* and *A. terreus* carry a third paralogous gene, which is a copy of *CYP51A* or *CYP51B*. Studies on *Aspergillus fumigatus* have shown that *CYP51B* is constitutively expressed, while *CYP51A* is expressed in an inducible manner. Neither *CYP51A* nor *CYP51B* is essential for *in vitro* growth and virulence, and only the simultaneous inactivation of both genes is lethal ([@B73]; [@B67]).

![Minor branch of the Fungal CYP51 Phylogenetic Tree. It has been permitted by the copyright holders through RightsLink.](fmicb-10-00691-g001){#F1}

A recent study also showed that CYP51 might have a number of indirect functions. In *C. albicans*, the deletion of *CYP51* (*ERG11*) reduces mycelial elongation and invasive growth, and causes defects of reactive oxygen elimination, resulting in reduced virulence *in vivo*. It is worth paying special attention that *ERG11*-deficient fungi are more susceptible to phagocytosis by macrophages, which indicates that CYP51 may be critical for the immune escape process in fungi ([@B180]).

Present in all animals, plants, fungi, in some protozoa and bacteria, the CYP51 protein located in the inner face of the endoplasmic reticulum is a membrane monospanning enzyme ([@B118]). And its N-terminus includes an amphipathic helix, which links the catalytic subunit to the lipid bilayer ([@B108]). Besides crystallographic structures of CYP51 proteins from some protozoa and bacteria, and the ligand-free CYP51 proteins from Homo sapiens (3JUV) and complexed with ketoconazole (3LD6) deposited in Protein Data Bank (PDB) ([@B156]). X-ray structures of CYP51 proteins of some fungi have already been described in literature, including CYP51 proteins from *Saccharomyces cerevisiae* complexed with the substrate lanosterol (4LXJ) and complexed with itraconazole (5EQB) ([@B108]), voriconazole (5HS1) and fluconazole (4WMZ) ([@B135]), from *C. albicans* complexed with posaconazole (5FSA) and the tetrazole-based antifungal drug candidate VT1161 (VT1) (5TZ1) ([@B65]), and CYP51B structure in complex with the VNI derivative (6CR2) and a tetrazole-based inhibitor VT-1598 (5FRB) from *A. fumigates* ([@B66]).

Together with information from the analysis of multiple-sequence alignment of CYP51 proteins from human and fungi including *S. cerevisiae, C. albicans, C. glabrata, C. tropicalis, C. krusei, C. dubliniensis, C. parapsilosis, A. fumigatus and Cryptococcus neoformans* showing that the identity varied between 36.5 and 93.9% among them ([Table 1](#T1){ref-type="table"}). The comprehensive comparative analysis of three-dimensional structures uncovered the basic understanding how CYP51 enzymes might maintain their conservation in human and fungi. As shown in [Figure 2](#F2){ref-type="fig"}, the majority of amino-acids residues conserved in the folding of chains might play an essential structural role for their enzymatic function. The residues forming the surface of CYP51 proteins active site were highly conserved, such as Y118, F126, G127, V130 and T311 from the CYP51 proteins helix B', B" helical turn and Helix I signature regions, respectively ([@B91]; [@B65]; [@B80]).

###### 

Comparison of identity (similarity) % of amino acid residue sequence of CYP51 from different organisms calculated using ClustalW2.

                      *Homo sapiens*   *Saccharomyces cerevisiae*   *Candida albicans*   *Candida glabrata*   *Candida tropicalis*   *Candida krusei*   *Candida dubliniensis*   *Candida parapsilosis*   *Cryptococcus neoformans*   *Aspergillus fumigatus A*   *Aspergillus fumigatus B*
  ------------------- ---------------- ---------------------------- -------------------- -------------------- ---------------------- ------------------ ------------------------ ------------------------ --------------------------- --------------------------- ---------------------------
  *H. sapiens*        --               38.0 (56.5)                  39.6 (54.7)          37.5 (55.6)          40.0 (54.7)            37.5 (56.8)        37.8 (54.1)              40.3 (58.0)              36.5 (54.8)                 38.1 (55.8)                 40.1 (58.6)
  *S. cerevisiae*     --               --                           64.5 (78.1)          84.1 (92.4)          65.5 (77.7)            61.8 (75.4)        63.8 (78.4)              66.6 (80.1)              44.0 (66.1)                 49.4 (68.9)                 51.1 (71.6)
  *C. albicans*       --               --                           --                   64.5 (77.7)          83.1 (91.5)            61.5 (76.9)        93.9 (98.1)              74.0 (86.0)              46.0 (66.2)                 48.3 (66.5)                 49.9 (68.0)
  *C. glabrata*       --               --                           --                   --                   64.7 (76.1)            62.8 (77.7)        65.0 (77.9)              66.9 (79.1)              43.4 (64.8)                 47.6 (66.3)                 52.2 (71.0)
  *C. tropicalis*     --               --                           --                   --                   --                     63.2 (77.2)        81.8 (91.5)              74.6 (85.8)              46.6 (67.5)                 48.9 (66.9)                 48.6 (66.2)
  *C. krusei*         --               --                           --                   --                   --                     --                 61.4 (77.6)              64.8 (78.8)              45.5 (63.6)                 46.9 (66.6)                 47.9 (68.2)
  *C. dubliniensis*   --               --                           --                   --                   --                     --                 --                       72.5 (85.8)              45.1 (66.2)                 48.3 (66.7)                 47.7 (65.9)
  *C. parapsilosis*   --               --                           --                   --                   --                     --                 --                       --                       48.6 (68.5)                 49.5 (68.3)                 48.3 (67.4)
  *C. neoformans*     --               --                           --                   --                   --                     --                 --                       --                       --                          47.4 (62.6)                 48.3 (65.5)
  *A. fumigatus A*    --               --                           --                   --                   --                     --                 --                       --                       --                          --                          63.6 (77.4)
  *A. fumigatus B*    --               --                           --                   --                   --                     --                 --                       --                       --                          --                          --

A. fumigatus A, Aspergillus fumigatus CYP51A;

A. fumigatus

B,

Aspergillus fumigatus

CYP51B.

![Structure alignment of primary structure of CYP51 from different organisms \> 80%. Structure alignment of primary structure of CYP51 from different organisms: *H. sapiens, S. cerevisiae, C. albicans, C. glabrata, C*. *tropicalis, C. krusei, C. dubliniensis, C. parapsilosis, A. fumigatus*, and *Cryptococcus neoformans*. The residues identical in all CYP51s are marked with black, the light gray show the residues conserved in more than 80% sequences. The sequences were from NCBI and CGD database and were aligned using the ClustalW2 program. Red arrow means the most conserved CYP51 active amino acid sites among diffierent species.](fmicb-10-00691-g002){#F2}

The conserved amino acid sequences can be classified into three motifs and six putative substrate recognition sites (SRS). Among the three motifs, the most conserved FXXGXXXCXG is a heme binding domain containing a heme axial Cys ligand; and the E--R--R triad, formed by the motifs EXXR and PER, contributes to locking the heme pocket into position and to guarantee stabilization of the core structure ([Figure 3](#F3){ref-type="fig"}). And among the six putative SRSs, the most thoroughly studied SRS1 and SRS4 can be used as landmarks of the fungal CYP51 ([@B90]) ([Figure 4](#F4){ref-type="fig"}).

![Sequence logos of the conserved CYP motifs from the tested fungi and human's CYP51. The sequences were from NCBI and CGD database and the consensus logos were generated by WebLogo (<http://weblogo.threeplusone.com/create.cgi>).](fmicb-10-00691-g003){#F3}

![**(A)** Predicted SRS1 (the positions 117--134) and SRS4 (the positions 305--314) of tested fungal CYP51 (*S. cerevisiae, C. albicans, C. glabrata, C. tropicalis, C. krusei, C. dubliniensis, C. parapsilosis, A. fumigatus*, and *Cryptococcus neoformans*). The sequences were from NCBI and CGD database and the consensus logos were generated by WebLogo (<http://weblogo.threeplusone.com/create.cgi>); **(B)** Location of SRS1(yellow) and SRS4 (blue) in *C. albicans* CYP51 (5v5z). HEME is shown in red. They are obtained from the published crystal data file from the PDB database, and then displayed by PyMOL Version 1.5.0.3.](fmicb-10-00691-g004){#F4}

To crystallize *C. albicans* CYP51 proteins complexes with posaconazole and a tetrazole-based drug candidate VT-1161, Hargrove et al. used *E. coli* cells to express and purify the truncated *C. albicans* CYP51 proteins (56 kDa) without the 48-amino-acid-long N-terminal membrane anchor sequence ([@B65]). The structural analysis of *C. albicans* CYP51 proteins complexes carried out by Hargrove et al. showed that posaconazole had contacts with a set of 28 residues of *C. albicans* CYP51 proteins, while VT-1161 interacts with 22 amino acid residues, and forms the H-bond between its trifluoroethoxyphenyl oxygen and the imidazole ring of His377 of *C. albicans* CYP51 proteins \[[Table 2](#T2){ref-type="table"} from [@B65] with slight modification\]. Further, the X-ray structure of *A. fumigates* CYP51B complex with the tetrazole-based inhibitor VT-1598 (5FRB) determined also by [@B66] showed the formation of an optimized hydrogen bond between the phenoxymethyl oxygen of VT-1598 and the imidazole ring nitrogen of His374 of *A. fumigates* CYP51B. Comparative structural analysis of the CYP51 proteins residue (His377 of *C. albicans* CYP51 proteins, His374 of *A. fumigates* CYP51B) among different organisms suggested it was highly conserved across fungal pathogens but not in human, supporting its fungus specificity and the role of H bonding in fungal CYP51/inhibitor complexes ([Figure 2](#F2){ref-type="fig"}, [5](#F5){ref-type="fig"}).

###### 

Posaconazole and a tetrazole-based drug candidate VT-1161 contacting residues (\<4.5 Å) in *C. albicans* CYP51 structures.

                    Drug      
  ----------------- --------- ---------------------
  Helix A′          Phe-58    
                    Ala-61    
                    Ala-62    
                    Tyr-64    Tyr-64
                    Gly-65    
  β1-β2 turn        Leu-88    
  Helix B′          Tyr-118   Tyr-118
                    Leu-121   Leu-121
                    Thr-122   Thr-122
                    Phe-126   Phe-126
  B″ helical turn   Ile-131   Ile-131
                    Tyr-132   Tyr-132
  Helix C                     
  Helix F″          Phe-228   Phe-228
                    Pro-230   Pro-230
                              
                              
                    Phe-233   Phe-233
  Helix I           Gly-303   Gly-303
                    Ile-304   Ile-304
                              
                    Gly-307   Gly-307
                    Gly-308   Gly-308
                    Thr-311   Thr-311
  K/β1--4 loop      Leu-376   Leu-376
                    His-377   **His-377, H-bond**
                    Ser-378   Ser-378
  β1--4 strand      Phe-380   Phe-380
  β4 hairpin        Tyr-505   Tyr-505
                    Ser-506   
                    Ser-507   Ser-507
                    Met-508   Met-508

Bold is to highlight the hydrogen bond formed between VT-1161 and

C. albicans

CYP51-His377.

![VT-1161 andVT-1598 forming the H bond. VT-1161 and VT-1598 forming the H bond with the His377 of *C. albicans* CYP51 and the His374 of *A. fumigates* CYP51B. **(A)** *C. albicans* CYP51-His377-VT-1161(5TZ1); **(B)** *A. fumigates* CYP51B-His374-VT-1598 (5FRB). They are obtained from the published crystal data file from the PDB database, and then displayed by PyMOL Version 1.5.0.3. The red dot line means H-bonds formed between VT-1161 and *C. albicans* CYP51-His377 in [Figure 5A](#F5){ref-type="fig"}, and H-bonds formed between VT-1598 and *A. fumigates* CYP51B-His374 in [Figure 5B](#F5){ref-type="fig"}.](fmicb-10-00691-g005){#F5}

After the first structure of CYP51 proteins with the N-terminal region from *S. cerevisiae* (5EQB) in complex with itraconazole was elucidated and deposited in PDB, Keniya et al. concluded that the conformations of the three full-length fungal Cyp51 structures binding to itraconazole were close to that of the N-truncated *C. albicans* Cyp51 with posaconazole. In comparison these had only slight variations in residues conformations, such as *C. glabrata* Cyp51 I71, T75, I240; *C. albicans* Cyp51 A62, Q66, I231 and *S. cerevisiae* Cyp51 V70, M74, I239, all of which were within the ligand binding pocket and may not be significant due to modest electron densities in this region. Besides, the structures showed *S. cerevisiae* Cyp51-fluconazole or itraconazole had the binding sites in near identical conformations ([@B135]; [@B80]). The X-ray crystal structures determined by [@B80] gives us insights into the CYP51 proteins reaction mechanism and emphasizes the identity of ligand-binding sites of fungal CYP51 families, providing a practical basis for the discovery and optimization of novel antifungals targeting at CYP51 families.

CYP51-Related Drug Resistance
=============================

In recent years, with the widespread use of CYP51-targeting drugs, drug-resistant *Candida, Cryptococcus*, and *Aspergillus* have emerged continuously. As shown in [Table 3](#T3){ref-type="table"}, in many resistant isolates, the decrease of susceptibility originated from mechanisms associated with CYP51, while other isolates not. Besides, transcription factors Pdr1 and Stb5, or the insertion of the Aft1 transposon into the *CYP51* promoter region, can also cause a decrease in the sensitivity of the drugs ([@B3]; [@B117]; [@B116]). Transcription factors of non-pathogenic species may also bring some information, such as Set4 in *S. cerevisiae*, which represses *CYP51* expression and reduces drug resistance ([@B143]). It is worth noting that drug resistance is often a combination of multiple mechanisms ([@B13]).

###### 

CYP51-related and CYP51-unrelated drug resistance.

  Resistance type   Mechanism                               Gene(s) involved                Transcription factor(s) involved   Species                                                                                                                                                        References
  ----------------- --------------------------------------- ------------------------------- ---------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  CYP51 Related     Drug-target point mutation              *CYP51*                                                            *C. albicans; C. tropicalis; C. krusei; C. glabrata; C. auris; C. parapsilosis; C. neoformans; C. gatti; A. fumigatus; A. flavus; S. apiospermum; T. asahii*   1
                    Regulation of drug target                                               Upc2; SREBPs                       *C. albicans; C. neoformans; A. fumigatus*                                                                                                                     2
                    Genomic plasticity                      *CYP51*                         Upc2;                              *C. albicans; C. glabrata; C. neoformans*                                                                                                                      3
                    Promoter Tandem Repeats                 *CYP51*                                                            *A. fumigatus*                                                                                                                                                 4
  CYP51 Unrelated   Efflux pump                             *CDR1;CDR2;MDR1*                Tac1;Mrr1                          *C. albicans; C. glabrata; C. krusei; C. neoformans; A. fumigatus*                                                                                             5
                    Compensatory ergosterol biosynthesis    *ERG3*                          Upc2                               *C. albicans; C. tropicalis; C. parapsilosis*                                                                                                                  6
                    Genomic plasticity                                                      Tac1                               *C. albicans*                                                                                                                                                  7
                    Biofilm formation                                                                                          *C. albicans; C. glabrata; C. parapsilosis; C. dubiliensis; C. tropicalis; C. neoformans; T. asahii; A. fumigatus*                                             8
                    Activation of Stress Response Passway   *HSP90;PKC1; Calcineurin;TOR*                                      *C. albicans; C. glabrata; C. neoformans A. terreus A. terreus; A. fumigatus; Paecilomyces variotii; Mucor* spp.                                               9
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The mechanisms associated with CYP51 are discussed below in detail.

*Candida* spp.
--------------

*Candida* spp., represented by *C. albicans*, is the most prominent pathogenic fungus. The spectrum of disease of invasive candidiasis ranges from minimally symptomatic candidaemia to fulminant sepsis with an associated mortality exceeding 70% ([@B121]). The resistance mechanisms of *Candida spp.* related with CYP51 includes point mutation, genomic plasticity, and upregulation of *CYP51* meditated by the transportation factor Upc2.

Point mutation (amino acid non-synonymous substitutions) of CYP51 proteins is a critical origination of reduced drug susceptibility. Three ways were proposed to explain the resistance mechanism: (1) the corresponding amino acids docked with azoles are changed, (2) the structure of the binding cavity is rearranged, leading to changed position of the azole molecule or the heme iron, disturbing the interaction between them, and (3) the access of the drug into the active site is blocked ([@B10]).

In *C. albicans*, mutations of CYP51 proteins amino acid sequences frequently occurs on 105--165, 266--287, and 405--488 ([@B102]). Among these mutations, N-terminal and C-terminal are more frequent than central regions, probably due to these terminal substitutions lead to changes in secondary and tertiary structure, especially substrate binding cavities, which are located in α-helix B, B′, C, and in their connection loops ([@B10]). And sequential replacement of ERG11 mutant alleles with wild-type alleles contributes to the reduction of resistance ([@B99]). The resistant *C. albicans* double point mutation Y132F G464S (Y140F G464S by *S. cerevisiae* numbering) were artificially introduced into *S. cerevisiae* CYP51, leading to a decrease in sensitivity of the latter ([@B134]). In addition, mutations located at different sites of CYP51 proteins provide different degrees of resistance enhancement. As an instance, K143R is stronger than F449V ([@B48]).

The non-albicans *Candida* (NCAC) species also contains amino acid non-synonymous substitutions, such as Y132F in *C. parapsilosis*, Y132F and K143R in *C. tropicalis* ([@B163]; [@B182]; [@B31]).

The newly emerged *C. auris* is a multi-drug resistant *Candida* that causes serious invasive infections, with a mortality rate approximate to 60% ([@B89]). *CYP51* point mutation plays an important role in pan-azole resistance of *C. auris*. Nine typical amino acid substitutions have been identified, three of which are closely associated with geographic clades: F126T in South Africa, Y132F in Venezuela, and Y132F or K143R in India and Pakistan ([@B98]).

Genomic plasticity, including aneuploidy and loss of heterozygosity (LOH), refers to the abnormal fungal chromosomal behavior induced by heat, oxidative stress or antifungal drugs. It is an important mechanism for fungal adaptation to the environment.

Aneuploidy is a reversible fungal chromosomal adaptive behavior in response to drug stress. If the "selectivity" of the drug disappears, the cells will return to the euploid state. Aneuploidy after azole stress was first discovered in *C. glabrata* and was detailed studied in *C. albicans* ([@B162]).

The aneuploidy of *C. albicans* chr1, chr3, chr5, chr6 and chrR has been reported under the stress of azoles treatments ([@B141]; [@B95]). Research on fluconazole-resistant strains has revealed that at least half of them carry aneuploid chromosomes. The duplication of the chr5's left arm in *C. albicans* \[named i(5L)\] results in multiple copies and overexpression of *CYP51* gene, contributing to azole resistance ([@B140]). Besides, aneuploidy of chr5 (carrying *TAC1*), chr3 (*MRR1* and *CDR1*), Chr4 or chr6 (*MDR1*) also reduce drug susceptibility ([@B141]). Some aneuploid *C. albicans* chromosomes source from the mitotic defect in the process of quasi-fertility ([@B49]). There also exists an additional mechanism that, two diploid cells and one tetraploid cell are connected to each other to form a "trimeric," then the tetraploid cell undergoes defective mitosis and results in two aneuploid progeny cells ([@B68]).

An "Evolution Trap" (ET) strategy was proposed to suppress the occurrence of aneuploidy. The aneuploidy of a whole microflora can develop into multiple random directions, but once a specific inducing factor (stress X) is used to strictly limit its development direction, another treatment (treatment Y) can be applied to eliminate this trend and inhibits the generation of resistance. Such strategy has successfully pulled the minimum inhibitory concentration (MIC) against *C. albicans* carrying aneuploidy-sourced resistance back to normal level ([@B28]).

Loss of heterozygosity is another branch of genomic plasticity leading to *Candida* species resistance. It is an irreversible process in diploid fungi, thus resulting the acquired resistance gene mutation (^∗^) become multiple (e.g., *ERG11/ERG11^∗^→ ERG11^∗^/ ERG11^∗^*), thus results in overexpression of such gene ([@B171]). LOH contains three mechanisms, (1) local recombination of chromosomes, (2) mitotic recombination between centromeres and related locus, (3) whole-chromosome loss and the remaining chromosome's duplication ([@B112]).

Transcription factors of *CYP51* are tightly related to drug resistance. The Zn~2~-Cys~6~ transcription factor Upc2, located in *Candida* spp., is highly relevant to the increase of azole sensitivity ([@B164]). It has been confirmed that when Upc2 in *C. albicans* or *C. parapsilosis* or Upc2A in *C. glabrata* is deleted, the susceptibility to azoles will be enhanced ([@B58]; [@B164]; [@B170]). The C-terminal domain (CTD) of Upc2 is a novel α-helical fold with a deep hydrophobic pocket. Treatment with azole reduces the membrane ergosterol level, then ergosterol molecules that are previously bound to CTD dissociates from Upc2p. Thereby Upc2p relocates from the cytoplasm to the nucleus to activate *CYP51* expression ([@B184]). It is worth noting that Upc2 only up-regulates the expression of *CYP51* under azole stress conditions ([@B72]).

The gain-of-function (GOF) mutation of Upc2 also contributes to *Candida* species increased drug resistance. Typical GOF point mutations inducing overexpression of *CYP51* in *C. albicans* include A643V, G648D, G648S, and Y642F ([@B43]; [@B47]). Point mutations in UPC2 can reduce the sensitivity to azoles in combination with amino acid substitution of CYP51. For example, when combined with the CYP51^G464S^ mutation, the MIC value of *C. albicans* carrying Upc2^G648D^ against fluconazole is increased from 4 μg/ml to 16 μg/ml ([@B137]).

Gain-of-function mutations were also found in *C. tropicalis* Upc2. Nucleotide substitutions T118G and G155A in *CtUpc2* promoter increase the expression of this gene, and amino acid substitution G392E in CtUpc2p enhances drug resistance when expressed heterologously in *S. cerevisiae* ([@B77]).

The GOF amino acid substitutions are often localized near the C terminus of Upc2p, where the activation domain of zinc-cluster transcription factors is found. Mutations in this region leading to reduced drug susceptibility include two possible mechanisms: (1) relieve Upc2 from a repressor that would otherwise keep this transcription factor inactive, (2) interfere with the transmembrane region of this protein, leading to Upc2p nuclear localization and initiation of *CYP51* transcription ([@B47]).

*Cryptococcus* spp.
-------------------

Cryptococcal meningitis (CM) is the most common infection caused by *Cryptococcus* spp., and is frequently recommended to be treated with fluconazole monotherapy in national guidelines. However, even with such treatment, the mortality of CM can exceed 50%, much of which owing to drug-induced *cryptococcal* resistance ([@B133]; [@B19]). Amino acid point mutation, genomic aneuploidy and Sre1-induced overexpression of *CYP51* account for the reduced azole susceptibility.

The amino acid point mutation G344S was found in CYP51 proteins of *Cryptococcus neoformans var. grubii*, resulting in multi-azole resistance ([@B79]). Besides, the substitution G484S may confer a change in the orientation of the P450 heme-binding domain, decreasing catalytic activity and azole binding of *Cryptococcus neoformans* CYP51 proteins (*Cn*CYP51 proteins) ([@B129]). And the substitution Y145F affords resistance to voriconazole but attenuates resistance to itraconazole and posaconazole ([@B149]). In *Cryptococcus gattii* CYP51 proteins, amino acid non-synonymous substitution N249D are deduced to result in azole resistance ([@B52]).

As for genomic aneuploidy, *Cryptococcus neoformans* Chr1 disomy, which is common in heteroresistant isolates, results in duplication of *CnCYP51* and reduced azole sensitivity. A recent report reveals that clinical fluconazole treatment can induce aneuploidy of *C. neoformans* in CM patients, and relapse of CM is associated with Chr1 disomy ([@B19]; [@B155]).

*Cryptococcus neoformans* is haploid and aneuploid cells of this species mainly derive from the uncoupling of cell growth and nuclear division ([@B5]). Unlike *C. albicans*, the aneuploidy of Chr1 in *C. neoformans* only repeats the entire chromosome without forming segmental isochromosomes ([@B83]). A study indicates the detailed mechanism causing aneuploidy: final degradation of the septum is affected by fluconazole during cytokinesis, resulting in Chr1 disomy multinucleated cells, and these cells exhibit an increased potential to proliferate in the presence of fluconazole ([@B5]). However, another study points out that the fluconazole-induced multinucleated cells fail to propagate to form colonies in the presence of fluconazole, and chromosome missegregation of *C. neoformans* dividing cells has not been detected, suggesting *C. neoformans* forms aneuploid clones directly from uninucleated cells under fluconazole stress ([@B27]).

Aneuploidy can be regulated by certain factors in *Cryptococcal* spp. For example, the decreased expression of *AIF1* (apoptosis-inducing factor) conduces to maintain Chr1 aneuploidy, thereby contributes to a stable repeat of *CYP51* and preserves resistance to azoles ([@B142]).

Sterol regulatory element-binding protein (SREBPs) regulate the *CYP51*s' expression in many species of fungal, including *C. neoformans* ([@B26]). Under azoles or hypoxic stress, SREBPs regulate the transcription of *CYP51* by binding to the sterol regulatory element (SRE) in the promoter

The SREBP in *C. neoformans* is Sre1. Sre1 is cleaved by Scp1and functions to regulate the expression of *CYP51*, thus plays a key role in drug resistance ([@B16]). Studies have shown that deletion of Sre1 converts the effect of azoles from fungistatic to fungicidal ([@B15]; [@B26]).

*Aspergillus* spp.
------------------

The ability *Aspergillus* spp. to adapt to mammal hosts or external environment is a vital fungal characteristic that leads to treatment failure and the emergence of resistant isolates worldwide. Non-synonymous substitution of amino acids, transcription factors SrbA and AtrR, tandem repeats, and Dap proteins constitute the CYP51-related resistance mechanisms of *Aspergillus* spp.

The lanosterol 14α-demethylase point amino acid mutations of *A. fumigatus* mainly appear in CYP51A, and G54, L98, G138, M220 and G448 are the hotspots ([@B41]). G54R/E/V and G138 lead to cross-resistance to itraconazole and posaconazole, and G448S results in voriconazole tolerance ([@B33]), while M220I/V/T/K can develop resistance to itraconazole, voriconazole, refconazole, and posaconazole ([@B106]). When the G138S point-substituted *CYP51A* in the resistant *A. fumigatus* was mutated back, the tolerance of the isolate diminished ([@B160]). Moreover, one mutation may have varied effects on resistance for different azoles. For example, in the heterologous expression experiment, G54W significantly reduces the susceptibility to itraconazole and posaconazole, while has almost no effect on voriconazole ([@B4]).

Amino acids substitution also occurs in non-fumigatus *Aspergillus* species. Four mutations of *A. flavus* CYP51C (S196F, A324P, N423D and V465M) are correlated with voriconazole resistance ([@B144]). For *A. clavatus* CYP51A, E483K and P486S mutations may narrow the azole transport and therefore confer lower susceptibility ([@B1]). As for *A. terreus* and related species, M217T and M217V mutations of CYP51Ap was found correlating with posaconazole resistance ([@B187]).

Notably, appliance of azole pesticides in agriculture is one of the reasons for the non-synonymous substitution of *A. fumigatus* CYP51 proteins. Mutations in this type include L98H, Y121F and T289A, which are often accompanied with tandem repeats of the *CYP51* promoter ([@B107]; [@B24]; [@B32]; [@B161]; [@B75]).

Tandem repeats include 34-base pair (TR34) and 46-base pair (TR46) ([@B154]). CBC (CGAAT binding complex) binds to CGAAT of -293 to -289 position in the CYP51 promoter and downregulates *CYP51A* expression. Tandem repeats reduce the affinity of CBC and the promoter, upregulating *CYP51A*. Mechanism researches indicate that the presence of eight different nucleotides at the 3′end of TR34 lead to lower CBC affinity ([@B57]).

The combination of *CYP51* promoter tandem repeat and CYP51 proteins point mutation contains TR34/L98H/S297T/F495I and TR46/Y121F/T289A, leading to broad-spectrum azole resistance. ([@B150]; [@B29]; [@B75]; [@B125]; [@B158]; [@B159]). Studies on TR34/L98H have shown that L98H can cause a flexible change in the BC loop and IH loop of *A. fumigatus* CYP51A (*Af*CYP51A), which changes the position of the tyrosine107 and tyrosine 121 side chains. This modifies the ligand access channels in the *Af*CYP51A and prevents the binding of azoles toward the active heme ([@B151]). Moreover, TR34/L98H doesn't incur a fitness cost or survival disadvantage to *A. fumigatus* ([@B11]). On the other hand, studies on TR46/Y121F/T289A indicate that the Y121F substitution seems to disrupt the H-bond between tyrosine and the heme center of *Af*CYP51A, resulting in the instability of enzyme's active center ([@B150]).

Besides, the insertion of Atf1 in the *A. fumigatus CYP51A* promoter may also be one of the factors leading to azole resistance ([@B3]). But it requires more researches to confirm whether the effect is direct.

The transportation factor SrbA, as one of *A. fumigatus* SREBPs, modulates the expression of *AfCYP51A*. Different from *C. neoformans*, Scap homologue is absent in *A. fumigatus*, and SrbA directly binds to the 34 mer of *AfCYP51A* promoter without cleavage, regulating the synthesis of ergosterol ([@B18]; [@B57]). SrbA is directly activated by azole stress and is associated with the intrinsic resistance of *A. fumigatus* to fluconazole ([@B152]). An azole-resistant strain with TR46/Y121F/T289A can be sensitized to azoles by deletion of srbA ([@B63]). The intrinsic expression of *CYP51* in such strain restores the MIC value to its original level ([@B176]).

AtrR is a newly discovered fungal-specific Zn2-Cys6 transcription factor in *Aspergillus* spp. It modulates the expression of *CYP51A* by directly binding to the promoter of this gene. Deletion of AtrR results in hypersensitivity to azoles and invalidates the CYP51A^G54E^ mutation that would otherwise render azole resistance ([@B62]).

Damage Resistance Protein A (DapA), which belongs to the cytochrome b5-like heme-binding damage resistance protein (Dap) family, responds to azole treatment in a concentration-dependent manner in *A. fumigatus*. It co-localizes with CYP51A/B protein in the endoplasmic reticulum (ER), and then binds to the heme group to stabilize these CYP51 proteins. DapA is highly associated with the intrinsic azole resistance of *A. fumigatus*, and the deletion of *DapA* leads to hypersensitivity to azoles ([@B153]). Studies show that DapA may indirectly sense the azole stress at the downstream of SrbA ([@B152]).

Traditional and Novel CYP51-Targeting Antifungal Agents
=======================================================

The study of azole antifungal antifungal agents can be traced back to 1944 ([@B179]). Since then, imidazole (clotrimazole, miconazole, econazole, and ketoconazole) and two generations of triazoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) successively entered into the clinic ([@B115]) (partly shown in [Table 4](#T4){ref-type="table"}). Besides, there are several other CYP51 inhibitors used in the treatment of topical or superficial fungal infections, such as oxiconazole, sertaconazole, luliconazole, efinaconazole, and ravaconazole.

###### 

Current antifungal CYP51 inhibitors.

  Name                Approval time   Clinical applications                                                                                                                                                 Adverse effects                                                                                                                 Remarks                                                                                      References
  ------------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------
  Ketoconazole(KCZ)   1981            Oral, vaginal, cutaneous and systemic candidiasis                                                                                                                     Liver damage, interference of the endocrine system, nausea, headache, abdominal pain, etc.                                      Oral formulation has withdrawn from Europe, Australia, and China.                            10
  Fluconazole(FCZ)    1988            Systemic *Candida* infection, cryptococcal meningitis, vaginal, oropharyngeal and esophageal candidiasis                                                              Nausea, vomiting, abdominal pain, gastrointestinal adverse reactions, reversible mild liver necrosis and thrombocytopenia       Adjuvants such as calcineurin inhibitors, heat shock protein 90 inhibitors have been found   11
  Itraconazole(ICZ)   1988            Invasive aspergillosis, superficial candidiasis, dermatophyte infection, sporotrichosis, blastomycosis, histoplasmosis, penicilliosis, and coccidioidomycosis, etc.   Gastrointestinal symptoms, cardiac failure, peripheral edema and hepatic inflammation                                                                                                                                        12
  Voriconazole(VCZ)   2002            Aspergillosis, candidiasis, scedosporium, and *Fusarium* infection                                                                                                    Neurotoxicity, visual toxicity, hepatotoxicity and skin malignancy                                                              Therapeutic drug testing (TDM) is required                                                   13
  Posaconazole(PCZ)   2006            *Aspergillus* and *Candida* infections, especially fluconazole or itraconazole resistant cases                                                                        Serious adverse reactions rarely exit. Non-serious adverse reactions include SeHeadache, nausea, and menstrual disorder, etc.                                                                                                14
  Isavuconazole       2015            Invasive aspergillosis and invasive mucormycosis                                                                                                                      Nausea, vomiting, diarrhea and hepatobiliary toxicity                                                                                                                                                                        15
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Both imidazoles and triazoles exits adverse reactions caused by inhibition of human CYP450 (such as CYP3A4 and CYP2C9), due to the strong affinity to heme iron ([@B71]). Fortunately, replacement by 1-tetrazole could attenuate such affinity. Based on this idea, new compounds VT-1611, VT-1129, and VT-1598 have been developed ([@B71]) ([Figure 6](#F6){ref-type="fig"}).
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VT-1598
-------

VT-1598 has a good affinity for the fungal CYP51 proteins, as the K~d~ of this compound to *A. fumigatus* CYP51B is 13 nM ([@B66]). Its antifungal spectrum is relatively broad. The MIC~50~ for azole-resistant *C. albicans* and *C. glabrata* is 0.124 and 1.19 μg/ml ([@B173]). Especially, the inhibition of VT-1598 against the clinical *Coccidioides* isolates is significantly better than that of fluconazole ([@B104]). The non-selective inhibition of VT-1598 to human CYP450 is weak, as IC~50~ for human CYP2C9 and CYP3A4 are both more than 200 μM, and the IC~50~ for CYP2C19 is 138 μM ([@B185]). When the oral dose (15 mg/kg/day) of VT-1598 is applied to mice, the C~max~ is about 13 mg/L, the C~24~ ~h~ level is 6.7 mg/L and the half-life period is 22 h in plasma ([@B51]).

VT-1598 has a high binding rate of plasma protein. When co-incubated with plasma at concentration of 1 mg or 5 mg/L *in vitro*, only less than 1% showed a free state ([@B51]). *In vivo*, when treated with 20 mg/kg of VT-1598 per day, the minimum plasma concentration (C~min~) was 32-fold greater than that of the 25 mg/kg dose of fluconazole ([@B22]).

In the mouse model, VT-1598 has been used alone or in combination with amphotericin liposomes, and has achieved good efficiency for cryptococcal meningitis caused by *C. neoformans* or *C. gatti* infection ([@B51]). VT-1598 has also achieved significant preventive effects against mucosal candidiasis induced by sensitive or resistant *Candida* spp. ([@B22]). In addition, VT-1598 can be used to treat central nervous system coccidioidomycosis infected by *C. posadasii* and *C. immitis* ([@B174]). In May 2016, FDA granted orphan drug designation to VT-1598 for the treatment of Valley fever, a disease caused by *Coccidioides* infection ([@B104]).

VT-1161 (Oteseconazole)
-----------------------

VT-1161 can tightly bind to the fungal CYP51 proteins and effectively inhibit the activity of such proteins. For example, the K~d~ of VT-1161 to *C. albicans* CYP51 proteins is less than 39 nM and IC~50~ ranges from 1.4 to 1.6 μM, resulting in the proportion of ergosterol to total sterols drop to only 3% ([@B166]). The MIC~50~ of VT-1161 against fluconazole-resistant *C. albicans* is 0.03 μg/ml ([@B23]). For *T. rubrum* CYP51 proteins, The K~d~ and IC~50~ values are 242 nM and 0.14 μM, respectively ([@B167]). Its non-selective inhibition of human CYP450 is also weak, appears in its IC~50~ of CYP2C9, CYP2C19 and CYP3A4 are 99, 72, and 65 μM. Pharmacokinetic experiments in mice showed that VT1161 has a wide distribution volume (1.4 L/kg), high oral bioavailability (73%), and long half-life period (\>48 h)([@B50]). Phase II clinical trials showed oral VT-1161 plasma exposure for the 150 mg/24 weeks' or 300 mg/24 weeks' treatment groups were 3.81 and 8.33 μg/mL ([@B21]).

Animal model studies have shown that VT1161 can be used to prevent or treat mucormycosis caused by *Rhizopus arrhizus*, and can also be used for treatment of mouse modeling infection or canine naturally occurring coccidioidomycosis ([@B146], [@B145]; [@B53]). In addition, in a mouse model, VT1611 can treat oropharynx or vaginal Candidiasis caused by fluconazole sensitive or resistant *C. albicans* ([@B23]). Phase II clinical trials indicate that oral VT1161 has a good effect on treating human vulvar candidiasis, with a satisfactory tolerance and a low incidence of adverse reactions ([@B21]). Currently, oral VT-1161 has completed Phase II clinical trials for moderate -- severe interdigital tinea pedis, vaginal candidiasis, and onychomycosis of the toenail. And phase III clinical trial is underway for Vaginal Candidiasis.

VT-1129 (Quilseconazole)
------------------------

VT-1129 has a similar skeleton to VT-1161, and shows a remarkable inhibitory activity against *Cryptococcus* CYP51 protein. For example, the Kd for *C. neoformans, C. gattii*, and *C. grubii* CYP51 proteins are about 11, 24, and 25 nM, respectively, and the corresponding IC50 are 0.16, 0.15, and 0.18 μM. VT-1129 can reduce the proportion of ergosterol to total sterols in C. neoformans to 11.5%, and only 0.12 μg/ml can totally inhibit the growth of *C. neoformans* ([@B165]; [@B172]). Its non-specific inhibition to human CYP450 is lower than that of the previous azole antifungals, appears in the IC50 to CYP2C9 and CYP2C19 are 87 and 110 μM, respectively, and for CYP3A4 is also higher than 79 μM ([@B165]). VT-1129 also inhibits the growth of azole or echinocandin resistant *C. glabrata* and *C. krusei* ([@B138]).

The pharmacokinetic experiments in mice model showed that VT-1129's half-life period is long (\>6 days). The plasma and brain concentrations were still above the MIC values even after 20 and 32 days stopping oral treatment of VT-1129. The non-linear pharmacokinetic model has been approved to describe the correlation between concentrations of VT-1129 in plasma and in brain ([@B172],[@B175]).

At present, the research on VT-1129 in animal models is mainly focused on cryptococcal meningitis. VT-1129 significantly reduces fungal burden and improve survival rates during treatments. When treated with a dose of ≥ 3 mg/kg/day, the fungal burden was undetectable in most mice even 20 days after dosing was stopped. And treating at a dose of 20 mg/kg once daily reached a maximal survival benefit (100%). Because VT-1129 plasma and brain concentrations are related with fungal burden reductions, the loading dose-maintenance dose (LD-MD) strategy to treat cryptococcal meningitis seems feasible ([@B172],[@B175]).

Conclusion and Perspectives
===========================

CYP51 plays a crucial role in fungal invasive growth, hyphae formation and virulence, and inhibitors targeting CYP51 have always been an important component of antifungal agents. Further researches on fungal CYP51s might set about from the following aspects: First, while the detailed crystal structures of several susceptible pathogenic fungi CYP51 have been elaborated, those of drug-resistant variants are still in hypothesis. If those structures were elucidated, targeting at common drug-resistant CYP51 protein variants could probably be promising. Second, it deserves more in-depth researches to find out why some kind of amino acid point mutations (such as G54W in *A. fumigatus CYP51A*) could have varied effects on resistance for different azoles. Such researches may provide important ideas to minimize drug resistance. Third, the study of model organisms may also bring some inspiration. Such as Set4, which targets to ergosterol gene promoters with a Hap1-dependent manner under hypoxic conditions in *S. cerevisiae*, could downregulates the expression of *CYP51*. Whether homologous proteins and similar mechanisms exist in pathogenic fungi requires further researches. As long as they exist, new remedies may be put forward to activate Set4 to inhibit azole-induced *CYP51* overexpression. Forth, it might be achievable to target other proteins as well as CYP51 simultaneously to maximize the therapeutic effect. There already exists some preliminary works focusing on this, and it is probably requisite to find out more accompanying targets. Fifth, the "Evolution Trap"(ET) strategy, which successfully restored the sensitivity of *C. albicans in vitro*, might be practiced *in vivo* to investigate whether similar effects exist in animal models and further in humans. Aside from these, it is also hopeful for pharmaceutics amelioration to improve treatment efficacy. Novel drug delivery systems, such as liposomes, may confer better oral bioavailability on azoles.
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